Cerity Partners
GMAB icon

Cerity Partners’s Genmab GMAB Stock Holding History

Cerity Partners’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Buy
39,904
+202
+0.5% +$5.37K ﹤0.01% 1943
2026
Q1 		$1.07M Sell
39,702
-891
-2% -$26.7K ﹤0.01% 1828
2025
Q4 		$1.25M Buy
40,593
+2,347
+6% +$73.2K ﹤0.01% 1599
2025
Q3 		$1.17M Buy
38,246
+15,412
+67% +$376K ﹤0.01% 1525
2025
Q2 		$472K Sell
22,834
-18,070
-44% -$371K ﹤0.01% 1897
2025
Q1 		$801K Sell
40,904
-10,360
-20% -$217K ﹤0.01% 1528
2024
Q4 		$1.21M Buy
51,264
+3,261
+7% +$71.6K ﹤0.01% 1329
2024
Q3 		$1.17M Buy
48,003
+6,103
+15% +$163K ﹤0.01% 1327
2024
Q2 		$1.05M Sell
41,900
-7,244
-15% -$205K ﹤0.01% 1205
2024
Q1 		$1.47M Sell
49,144
-5,909
-11% -$174K ﹤0.01% 1105
2023
Q4 		$1.75M Buy
55,053
+42,661
+344% +$1.34M 0.01% 802
2023
Q3 		$437K Sell
12,392
-52,072
-81% -$1.98M ﹤0.01% 1026
2023
Q2 		$2.45M Buy
64,464
+28
+0% +$1.12K 0.01% 670
2023
Q1 		$2.43M Sell
64,436
-2,778
-4% -$107K 0.01% 663
2022
Q4 		$2.85M Buy
67,214
+1,072
+2% +$44.2K 0.02% 468
2022
Q3 		$2.13M Buy
66,142
+5,182
+9% +$182K 0.03% 363
2022
Q2 		$1.98M Buy
60,960
+5,230
+9% +$169K 0.02% 405
2022
Q1 		$2.02M Sell
55,730
-11,319
-17% -$388K 0.03% 328
2021
Q4 		$2.65M Buy
67,049
+7,545
+13% +$315K 0.04% 278
2021
Q3 		$2.6M Sell
59,504
-167
-0.3% -$7.5K 0.06% 228
2021
Q2 		$2.44M Buy
59,671
+66
+0.1% +$2.55K 0.05% 237
2021
Q1 		$1.96M Sell
59,605
-2,691
-4% -$101K 0.05% 259
2020
Q4 		$2.53M Buy
62,296
+7,439
+14% +$278K 0.08% 183
2020
Q3 		$2.01M Buy
+54,857
New +$1.98M 0.08% 168
2019
Q4 		– Sell
-12,340
Closed -$250K – 548
2019
Q3 		$250K Buy
+12,340
New +$243K 0.01% 422

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cerity Partners's GMAB Position: Q2 2026 in Review

Cerity Partners increased its Genmab (GMAB) stake by 0.51% in Q2 2026, buying an estimated $5.37K and bringing the position to 39,904 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1943.

Cerity Partners first reported a position in GMAB in Q3 2019 and has held it in 25 quarters since. The position peaked at $2.85M in Q4 2022. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Cerity Partners held 39,904 shares of Genmab worth $1.1M as of Q2 2026.
  • Cerity Partners bought 202 Genmab shares in Q2 2026, an estimated $5.37K.
  • Genmab made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1943 holding.
  • Cerity Partners first reported a position in Genmab in Q3 2019 and has held it in 25 quarters since.
  • Cerity Partners's Genmab position peaked at $2.85M in Q4 2022.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.